Jaguar Health Inc (NASDAQ: JAGX)’s stock price has plunge by -11.41relation to previous closing price of 0.18. Nevertheless, the company has seen a 73.75% surge in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-16 that Jaguar Health (NASDAQ: JAGX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new license for a chemo mouth treatment. Jaguar Health is looking to treat chemo mouth, a side effect of chemotherapy, with Gelclair.
Is It Worth Investing in Jaguar Health Inc (NASDAQ: JAGX) Right Now?
The stock has a 36-month beta value of 1.00. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JAGX is 262.69M, and at present, short sellers hold a 7.50% of that float. On April 22, 2024, the average trading volume of JAGX was 58.63M shares.
JAGX’s Market Performance
JAGX stock saw an increase of 73.75% in the past week, with a monthly gain of 96.37% and a quarterly increase of 54.89%. The volatility ratio for the week is 40.81%, and the volatility levels for the last 30 days are 22.25% for Jaguar Health Inc (JAGX). The simple moving average for the last 20 days is 59.59% for JAGX stock, with a simple moving average of -41.48% for the last 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at 81.80% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.14% of loss for the given period.
Volatility was left at 22.25%, however, over the last 30 days, the volatility rate increased by 40.81%, as shares surge +98.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +74.92% upper at present.
During the last 5 trading sessions, JAGX rose by +73.75%, which changed the moving average for the period of 200-days by -71.41% in comparison to the 20-day moving average, which settled at $0.1022. In addition, Jaguar Health Inc saw 3.63% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -3.48 for the present operating margin
- 0.73 for the gross margin
The net margin for Jaguar Health Inc stands at -4.23. The total capital return value is set at -0.92. Equity return is now at value -1919.14, with -84.10 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.88 points at debt to capital in total, while cash flow to debt ratio is standing at -0.92. The debt to equity ratio resting at 7.3. The interest coverage ratio of the stock is -5.31.
Currently, EBITDA for the company is -31.53 million with net debt to EBITDA at -0.97. When we switch over and look at the enterprise to sales, we see a ratio of 7.58. The receivables turnover for the company is 4.47for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.
Conclusion
To sum up, Jaguar Health Inc (JAGX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
